| Sergey Shvygin, MD | |
|
1906 Belleview Ave Se, Roanoke, VA 24014-1838 | |
| (540) 981-7000 | |
| (540) 853-0931 |
| Full Name | Sergey Shvygin |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 31 Years |
| Location | 1906 Belleview Ave Se, Roanoke, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760647051 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 55344 (Wisconsin) | Secondary |
| 207Q00000X | Family Medicine | 0101248531 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Carilion Home Care Services - Roanoke | Roanoke, VA | Home health agency |
| Carilion Medical Center | Roanoke, VA | Hospital |
| Lourdes Hospital | Binghamton, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carilion Medical Center | 9830096585 | 758 |
| Cogent Medical Care Pc | 7315836780 | 170 |
News Archive
Traumatic experiences can become deeply entrenched in a person's memory. How can fears following a traumatic event be reduced in the long term and prevented from becoming a permanent stress-related disorder? Researchers at the Mainz University Medical Center have recently shed new light on these questions.
Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center.
A qualitative study led by researchers at the Johns Hopkins Bloomberg School of Public Health yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services and financial assistance to reduce long-term, breast cancer-related economic burden.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
› Verified 7 days ago
| Entity Name | Carilion Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206370 PECOS PAC ID: 5890607253 Enrollment ID: O20031106000273 |
News Archive
Traumatic experiences can become deeply entrenched in a person's memory. How can fears following a traumatic event be reduced in the long term and prevented from becoming a permanent stress-related disorder? Researchers at the Mainz University Medical Center have recently shed new light on these questions.
Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center.
A qualitative study led by researchers at the Johns Hopkins Bloomberg School of Public Health yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services and financial assistance to reduce long-term, breast cancer-related economic burden.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
› Verified 7 days ago
| Entity Name | Carilion Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730123472 PECOS PAC ID: 9830096585 Enrollment ID: O20040107000472 |
News Archive
Traumatic experiences can become deeply entrenched in a person's memory. How can fears following a traumatic event be reduced in the long term and prevented from becoming a permanent stress-related disorder? Researchers at the Mainz University Medical Center have recently shed new light on these questions.
Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center.
A qualitative study led by researchers at the Johns Hopkins Bloomberg School of Public Health yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services and financial assistance to reduce long-term, breast cancer-related economic burden.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
› Verified 7 days ago
| Entity Name | Carilion Rockbridge Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174636021 PECOS PAC ID: 4789658261 Enrollment ID: O20040820000838 |
News Archive
Traumatic experiences can become deeply entrenched in a person's memory. How can fears following a traumatic event be reduced in the long term and prevented from becoming a permanent stress-related disorder? Researchers at the Mainz University Medical Center have recently shed new light on these questions.
Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center.
A qualitative study led by researchers at the Johns Hopkins Bloomberg School of Public Health yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services and financial assistance to reduce long-term, breast cancer-related economic burden.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
› Verified 7 days ago
| Entity Name | Carilion Giles Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194718304 PECOS PAC ID: 3678670221 Enrollment ID: O20070516000487 |
News Archive
Traumatic experiences can become deeply entrenched in a person's memory. How can fears following a traumatic event be reduced in the long term and prevented from becoming a permanent stress-related disorder? Researchers at the Mainz University Medical Center have recently shed new light on these questions.
Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center.
A qualitative study led by researchers at the Johns Hopkins Bloomberg School of Public Health yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services and financial assistance to reduce long-term, breast cancer-related economic burden.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
› Verified 7 days ago
| Entity Name | Hospitalist Medicine Physicians Of Virginia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770756991 PECOS PAC ID: 5698842235 Enrollment ID: O20081118000789 |
News Archive
Traumatic experiences can become deeply entrenched in a person's memory. How can fears following a traumatic event be reduced in the long term and prevented from becoming a permanent stress-related disorder? Researchers at the Mainz University Medical Center have recently shed new light on these questions.
Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center.
A qualitative study led by researchers at the Johns Hopkins Bloomberg School of Public Health yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services and financial assistance to reduce long-term, breast cancer-related economic burden.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
› Verified 7 days ago
| Entity Name | Hospitalist Medicine Physicians Of Fredericksburg, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447577572 PECOS PAC ID: 7719179407 Enrollment ID: O20101013000902 |
News Archive
Traumatic experiences can become deeply entrenched in a person's memory. How can fears following a traumatic event be reduced in the long term and prevented from becoming a permanent stress-related disorder? Researchers at the Mainz University Medical Center have recently shed new light on these questions.
Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center.
A qualitative study led by researchers at the Johns Hopkins Bloomberg School of Public Health yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services and financial assistance to reduce long-term, breast cancer-related economic burden.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
› Verified 7 days ago
| Entity Name | Mary Washington Medical Group Hospitalist Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750826277 PECOS PAC ID: 1456629369 Enrollment ID: O20170619001149 |
News Archive
Traumatic experiences can become deeply entrenched in a person's memory. How can fears following a traumatic event be reduced in the long term and prevented from becoming a permanent stress-related disorder? Researchers at the Mainz University Medical Center have recently shed new light on these questions.
Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center.
A qualitative study led by researchers at the Johns Hopkins Bloomberg School of Public Health yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services and financial assistance to reduce long-term, breast cancer-related economic burden.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
› Verified 7 days ago
| Entity Name | Hospitalist Medicine Physicians Of Virginia - Richmond, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699311324 PECOS PAC ID: 2860829207 Enrollment ID: O20200225002340 |
News Archive
Traumatic experiences can become deeply entrenched in a person's memory. How can fears following a traumatic event be reduced in the long term and prevented from becoming a permanent stress-related disorder? Researchers at the Mainz University Medical Center have recently shed new light on these questions.
Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center.
A qualitative study led by researchers at the Johns Hopkins Bloomberg School of Public Health yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services and financial assistance to reduce long-term, breast cancer-related economic burden.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
› Verified 7 days ago
| Entity Name | Hospitalist Medicine Physicians Of Virginia - Richmond Ii, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316583040 PECOS PAC ID: 9234566555 Enrollment ID: O20200227000002 |
News Archive
Traumatic experiences can become deeply entrenched in a person's memory. How can fears following a traumatic event be reduced in the long term and prevented from becoming a permanent stress-related disorder? Researchers at the Mainz University Medical Center have recently shed new light on these questions.
Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center.
A qualitative study led by researchers at the Johns Hopkins Bloomberg School of Public Health yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services and financial assistance to reduce long-term, breast cancer-related economic burden.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sergey Shvygin, MD 1906 Belleview Ave Se, Roanoke, VA 24014-1838 Ph: (540) 981-7000 | Sergey Shvygin, MD 1906 Belleview Ave Se, Roanoke, VA 24014-1838 Ph: (540) 981-7000 |
News Archive
Traumatic experiences can become deeply entrenched in a person's memory. How can fears following a traumatic event be reduced in the long term and prevented from becoming a permanent stress-related disorder? Researchers at the Mainz University Medical Center have recently shed new light on these questions.
Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.
Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center.
A qualitative study led by researchers at the Johns Hopkins Bloomberg School of Public Health yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services and financial assistance to reduce long-term, breast cancer-related economic burden.
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
› Verified 7 days ago
Lindsay R Wilson, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1314 Peters Creek Rd Nw, Roanoke, VA 24017 Phone: 540-562-5703 Fax: 540-562-4278 | |
Vitaly Kishinyovsky, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2145 Mount Pleasant Blvd Se, Roanoke, VA 24014 Phone: 540-427-9200 | |
Sujina Pradhan, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1906 Belleview Ave Se, Roanoke, VA 24014 Phone: 540-981-7000 | |
Dr. Uzma M Ali, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2133 Pelham Dr, Roanoke, VA 24018 Phone: 540-283-9039 Fax: 540-324-4164 | |
Erin K. Howes, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3707 Brambleton Ave Ste 2, Roanoke, VA 24018 Phone: 540-725-7800 Fax: 540-989-6752 | |
Christy Arthur, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3707 Brambleton Ave, Roanoke, VA 24018 Phone: 540-725-7800 | |
Todd Palmerton, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6415 Peters Creek Rd, Roanoke, VA 24019 Phone: 540-265-5500 |